Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Net Cash Flow (2020 - 2025)

Tarsus Pharmaceuticals has reported Net Cash Flow over the past 6 years, most recently at $70.9 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $70.9 million for Q4 2025, up 189.96% from a year ago — trailing twelve months through Dec 2025 was $88.8 million (up 169.63% YoY), and the annual figure for FY2025 was $88.8 million, up 169.63%.
  • Net Cash Flow for Q4 2025 was $70.9 million at Tarsus Pharmaceuticals, up from $16.1 million in the prior quarter.
  • Over the last five years, Net Cash Flow for TARS hit a ceiling of $119.9 million in Q3 2023 and a floor of -$97.8 million in Q4 2022.
  • Median Net Cash Flow over the past 5 years was -$3.3 million (2023), compared with a mean of $902700.0.
  • Biggest five-year swings in Net Cash Flow: soared 844.6% in 2021 and later plummeted 4469.8% in 2024.
  • Tarsus Pharmaceuticals' Net Cash Flow stood at -$12.5 million in 2021, then plummeted by 684.58% to -$97.8 million in 2022, then surged by 98.24% to -$1.7 million in 2023, then plummeted by 4469.8% to -$78.8 million in 2024, then soared by 189.96% to $70.9 million in 2025.
  • The last three reported values for Net Cash Flow were $70.9 million (Q4 2025), $16.1 million (Q3 2025), and -$79.1 million (Q2 2025) per Business Quant data.